{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:29:09Z","timestamp":1786980549604,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"JSPS KAKENHI","award":["JP 19K11478"],"award-info":[{"award-number":["JP 19K11478"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s10157-020-02007-2","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T12:26:21Z","timestamp":1609935981000},"page":"365-375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats"],"prefix":"10.1007","volume":"25","author":[{"given":"Shohei","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Sugaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Ohata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Natsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiika","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuho","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiko","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Shibagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0786-3197","authenticated-orcid":false,"given":"Atsuko","family":"Kamijo-Ikemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"issue":"4","key":"2007_CR1","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s13300-020-00798-x","volume":"11","author":"WL Yin","year":"2020","unstructured":"Yin WL, Bain SC, Min T. The effect of glucagon-like peptide-1 receptor agonists on renal outcomes in type 2 diabetes. Diabetes Ther. 2020;11(4):835\u201344.","journal-title":"Diabetes Ther"},{"issue":"2","key":"2007_CR2","doi-asserted-by":"publisher","first-page":"F443","DOI":"10.1152\/ajprenal.00280.2019","volume":"318","author":"AVR Hviid","year":"2020","unstructured":"Hviid AVR, S\u00f8rensen CM. Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation. Am J Physiol Renal Physiol. 2020;318(2):F443\u201354.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"2007_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/ki.2013.427","volume":"85","author":"H Fujita","year":"2014","unstructured":"Fujita H, Morii T, Fujishima H, Sato T, Shimizu T, Hosoba M, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int. 2014;85(3):579\u201389.","journal-title":"Kidney Int"},{"issue":"23","key":"2007_CR4","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K\u00f8ber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"},{"issue":"8","key":"2007_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2007_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515\u201327.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2007_CR7","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/dc14-2883","volume":"39","author":"MJ Davies","year":"2016","unstructured":"Davies MJ, Bain SC, Atkin SL, Rossing P, Scott D, Shamkhalova MS, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2016;39(2):222\u201330.","journal-title":"Diabetes Care"},{"issue":"6","key":"2007_CR8","doi-asserted-by":"publisher","first-page":"F1409","DOI":"10.1152\/ajprenal.00579.2019","volume":"318","author":"EP Jensen","year":"2020","unstructured":"Jensen EP, M\u00f8ller S, Hviid AV, Veedfald S, Holst JJ, Pedersen J, et al. GLP-1-induced renal vasodilation in rodents depends exclusively on the known GLP-1 receptor and is lost in prehypertensive rats. Am J Physiol Renal Physiol. 2020;318(6):F1409\u201317.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"12","key":"2007_CR9","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1007\/s11255-019-02274-3","volume":"51","author":"L Xue","year":"2019","unstructured":"Xue L, Pan Z, Yin Q, Zhang P, Zhang J, Qi W. Liraglutide promotes autophagy by regulating the AMPK\/mTOR pathway in a rat remnant kidney model of chronic renal failure. Int Urol Nephrol. 2019;51(12):2305\u201313.","journal-title":"Int Urol Nephrol"},{"issue":"10","key":"2007_CR10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrneph.2017.123","volume":"13","author":"MHA Muskiet","year":"2017","unstructured":"Muskiet MHA, Tonneijck L, Smits MM, van Baar MJB, Kramer MHH, Hoorn EJ, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017;13(10):605\u201328.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"2007_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1538\/expanim.57.111","volume":"57","author":"K Matsui","year":"2008","unstructured":"Matsui K, Ohta T, Oda T, Sasase T, Ueda N, Miyajima K, et al. Diabetes-associated complications in Spontaneously Diabetic Torii fatty rats. Exp Anim. 2008;57(2):111\u201321.","journal-title":"Exp Anim"},{"issue":"6","key":"2007_CR12","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1159\/000503926","volume":"44","author":"J Tanabe","year":"2019","unstructured":"Tanabe J, Ogura Y, Nakabayashi M, Nagai Y, Watanabe S, Sugaya T, et al. The possibility of urinary liver-type fatty acid-binding protein as a biomarker of renal hypoxia in spontaneously diabetic torii fatty rats. Kidney Blood Press Res. 2019;44(6):1476\u201392.","journal-title":"Kidney Blood Press Res"},{"issue":"15","key":"2007_CR13","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.lfs.2006.11.054","volume":"80","author":"T Tomohiro","year":"2007","unstructured":"Tomohiro T, Kumai T, Sato T, Takeba Y, Kobayashi S, Kimura K. Hypertension aggravates glomerular dysfunction with oxidative stress in a rat model of diabetic nephropathy. Life Sci. 2007;80(15):1364\u201372.","journal-title":"Life Sci"},{"issue":"11","key":"2007_CR14","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.2337\/db11-1824","volume":"61","author":"A Mima","year":"2012","unstructured":"Mima A, Hiraoka-Yamomoto J, Li Q, Kitada M, Li C, Geraldes P, et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKC\u03b2 activation in diabetes. Diabetes. 2012;61(11):2967\u201379.","journal-title":"Diabetes"},{"issue":"4","key":"2007_CR15","doi-asserted-by":"publisher","first-page":"F854","DOI":"10.1152\/ajprenal.00258.2017","volume":"313","author":"SC Thomson","year":"2017","unstructured":"Thomson SC, Kashkouli A, Liu ZZ, Singh P. Renal hemodynamic effects of glucagon-like peptide-1 agonist are mediated by nitric oxide but not prostaglandin. Am J Physiol Renal Physiol. 2017;313(4):F854\u20138.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"5","key":"2007_CR16","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.3892\/mmr.2014.2555","volume":"10","author":"SJ Zhou","year":"2014","unstructured":"Zhou SJ, Bai L, Lv L, Chen R, Li CJ, Liu XY, et al. Liraglutide ameliorates renal injury in streptozotocin-induced diabetic rats by activating endothelial nitric oxide synthase activity via the downregulation of the nuclear factor-\u03baB pathway. Mol Med Rep. 2014;10(5):2587\u201394.","journal-title":"Mol Med Rep"},{"issue":"5","key":"2007_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/labinvest.2008.23","volume":"88","author":"S Mohan","year":"2008","unstructured":"Mohan S, Reddick RL, Musi N, Horn DA, Yan B, Prihoda TJ, et al. Diabetic eNOS knockout mice develop distinct macro- and microvascular complications. Lab Invest. 2008;88(5):515\u201328.","journal-title":"Lab Invest"},{"issue":"7","key":"2007_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11892-017-0879-y","volume":"17","author":"M Kitada","year":"2017","unstructured":"Kitada M, Ogura Y, Monno I, Koya D. Regulating autophagy as a therapeutic target for diabetic nephropathy. Curr Diab Rep. 2017;17(7):53.","journal-title":"Curr Diab Rep"},{"key":"2007_CR19","doi-asserted-by":"crossref","unstructured":"Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A et al (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12(1):1\u2013222.","DOI":"10.1080\/15548627.2015.1100356"},{"issue":"6","key":"2007_CR20","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2215\/CJN.11511114","volume":"10","author":"HJ Lambers Heerspink","year":"2015","unstructured":"Lambers Heerspink HJ, Gansevoort RT. Albuminuria is an appropriate therapeutic target in patients with CKD: the pro view. Clin J Am Soc Nephrol. 2015;10(6):1079\u201388.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2007_CR21","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1681\/ASN.2006070778","volume":"18","author":"CW Park","year":"2007","unstructured":"Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db\/db mice. J Am Soc Nephrol. 2007;18(4):1227\u201338.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2007_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1124\/jpet.118.254821","volume":"369","author":"V Sukumaran","year":"2019","unstructured":"Sukumaran V, Tsuchimochi H, Sonobe T, Shirai M, Pearson JT. Liraglutide improves renal endothelial function in obese Zucker rats on a high-salt diet. J Pharmacol Exp Ther. 2019;369(3):375\u201388.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"2007_CR23","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1681\/ASN.2016070731","volume":"28","author":"T Yamamoto","year":"2017","unstructured":"Yamamoto T, Takabatake Y, Takahashi A, Kimura T, Namba T, Matsuda J, et al. High-fat diet-induced lysosomal dysfunction and impaired autophagic flux contribute to lipotoxicity in the kidney. J Am Soc Nephrol. 2017;28(5):1534\u201351.","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-02007-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-020-02007-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-02007-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T15:02:59Z","timestamp":1670684579000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-020-02007-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["2007"],"URL":"https:\/\/doi.org\/10.1007\/s10157-020-02007-2","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"26 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TS is the Director and a senior scientist at CMIC Holdings Co., Ltd., and KO is a scientist at CMIC Holdings Co., Ltd., which produced the kits for L-FABP analysis. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}